Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Assets (2016 - 2025)

Cardiff Oncology's Assets history spans 15 years, with the latest figure at $61.9 million for Q4 2025.

  • For Q4 2025, Assets fell 36.33% year-over-year to $61.9 million; the TTM value through Dec 2025 reached $61.9 million, down 36.33%, while the annual FY2025 figure was $61.9 million, 36.33% down from the prior year.
  • Assets for Q4 2025 was $61.9 million at Cardiff Oncology, down from $63.8 million in the prior quarter.
  • Across five years, Assets topped out at $149.5 million in Q4 2021 and bottomed at $61.9 million in Q4 2025.
  • The 5-year median for Assets is $97.3 million (2023), against an average of $101.7 million.
  • The largest annual shift saw Assets skyrocketed 996.64% in 2021 before it tumbled 36.33% in 2025.
  • A 5-year view of Assets shows it stood at $149.5 million in 2021, then dropped by 22.3% to $116.2 million in 2022, then dropped by 29.74% to $81.6 million in 2023, then grew by 19.05% to $97.2 million in 2024, then crashed by 36.33% to $61.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Assets are $61.9 million (Q4 2025), $63.8 million (Q3 2025), and $75.7 million (Q2 2025).